A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Chloroprocaine
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.
Halothane
Satralizumab
The serum concentration of Levocetirizine can be decreased when it is combined with Satralizumab.
Halothane
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Levocetirizine is combined with Oliceridine.
Halothane
Abametapir
The serum concentration of Levocetirizine can be increased when it is combined with Abametapir.
Halothane
Tucatinib
The metabolism of Tucatinib can be decreased when combined with Levocetirizine.
Halothane
Cenobamate
The serum concentration of Levocetirizine can be decreased when it is combined with Cenobamate.
Halothane
Lasmiditan
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Lasmiditan.
Halothane
Lefamulin
Lefamulin may increase the QTc-prolonging activities of Levocetirizine.
Halothane
Entrectinib
The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Entrectinib.
Halothane
Esketamine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Esketamine.
Halothane
Deoxyepinephrine
The therapeutic efficacy of Deoxyepinephrine can be increased when used in combination with Levocetirizine.
Halothane
Theodrenaline
The therapeutic efficacy of Theodrenaline can be increased when used in combination with Levocetirizine.
Halothane
Racepinephrine
The therapeutic efficacy of Racepinephrine can be increased when used in combination with Levocetirizine.
Halothane
Protokylol
The therapeutic efficacy of Protokylol can be increased when used in combination with Levocetirizine.
Halothane
Levonordefrin
The therapeutic efficacy of Levonordefrin can be increased when used in combination with Levocetirizine.
Halothane
Agmatine
Agmatine may increase the anticholinergic activities of Levocetirizine.
Halothane
Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione
Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione may increase the anticholinergic activities of Levocetirizine.
Halothane
Fenoterol
Fenoterol may increase the anticholinergic activities of Levocetirizine.
Halothane
Chloroprocaine
Chloroprocaine may increase the anticholinergic activities of Levocetirizine.
Halothane
Cannabinol
The risk or severity of adverse effects can be increased when Cannabinol is combined with Levocetirizine.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3